SEOUL (Reuters): South Korean drugmaker Celltrion Inc said on Friday (Nov 6) patients treated with its experimental Covid-19 antibody drug in a small-size early-stage trial showed at least a 44% improvement in recovery time.
The result bodes well for Celltrion, which plans to seek conditional approval for the monoclonal antibody treatment, CT-P59, for emergency use by the end of this year in South Korea.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!